PRESS RELEASES

Coulter Partners Finds Chief Medical Officer for Memo Therapeutics AG

(July 13, 2021) Coulter Partners was very pleased to partner recently with Memo Therapeutics AG, an innovator in the field of antibody discovery and development, to secure the appointment of Dr. George Badita as Chief Medical Officer.

Dr. Badita is an MD, board certified in Infectious Diseases, with over 30 years of experience in life sciences in hospital, academic, and pharmaceutical industry settings. He has over 20 years of experience in drug development, particularly in Anti-infectives, as well as in Oncology, Immunology and Respiratory areas. He held successive Clinical Development senior positions at various European and US companies and contributed to bring to market several anti-infectives.

“We are very pleased to welcome George to Memo Therapeutics as a key member of the leadership team” declared Dr. Karsten Fischer, CEO. “George brings his extensive expertise in Translational Medicine and Clinical Drug Development as the company is in a pivotal stage of growth and prepares to transition to a clinical-stage organization. I thank the Coulter Partners team for their outstanding professional support in securing George’s appointment.”

About Memo Therapeutics AG

Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. The company’s antibody discovery platform uses robust, simple and fast microfluidic single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery at unprecedented speed, efficiency and sensitivity.

The platform captures and preserves entire B-cell repertoires from any donor species and any B-cell type in recombinant form for display using mammalian cells. The antibody repertoires are subsequently screened in single-cell format using microfluidic screening technology that can assess millions of candidate antibodies directly in functional assays, resulting in recombinant clonal cell lines expressing monoclonal antibodies (mAbs) with the desired functional properties.

Exploiting the power of its microfluidic single-cell molecular cloning and screening technologies, Memo Therapeutics AG engages in antibody discovery across species and indications for proprietary and partnered projects. The company’s current pipeline features programs in infectious diseases and immuno-oncology. Memo Therapeutics AG is a private company located in Bio-Technopark Zurich, Switzerland. For further information visit: Memo Therapeutics AG (“Memo”)

About Coulter Partners

Coulter Partners is a board and senior level executive search specialist focussed exclusively on global Life Sciences. From our offices in the UK, Europe, North America and APAC, we work together across boundaries and
disciplines to build outstanding leadership teams for our clients in the pharmaceuticals, biotechnology, medical devices, diagnostics, heath tech, CRO and services sectors. Our industry leading reputation is founded on deep sector knowledge and innovative thinking. Our strategy is built on a unique team culture and true global reach. Our goal is to bring you the world’s best talent.

Share This Article
M&A Conference Info Sept 2021